Literature DB >> 3940420

Sensitivity of three activated partial thromboplastin time reagents to coagulation factor deficiencies.

D C Turi, E I Peerschke.   

Abstract

Three activated partial thromboplastin time (APTT) reagent test systems, General Diagnostics Automated APTT, American Dade Actin FS, and Pacific Hemostasis (Thromboscreen KAPTT) reagent, containing different activators for the APTT assay, were evaluated for their precision and sensitivity to factor deficiencies in the intrinsic coagulation system. The data suggest that micronized silica and ellagic acid reagent systems were similar in sensitivity to Factor VIII, X, and XII deficiencies, whereas, the micronized kaolin reagent was significantly less sensitive to these deficiencies. Factor XI deficiency was detected equally well with the use of all three reagent systems. The ellagic acid reagent was somewhat more sensitive to Factor IX deficiency than the micronized silica reagent, and the micronized kaolin reagent was again least sensitive. Both the micronized silica and ellagic acid based reagents were insensitive to all but severe deficiencies in prekallikrein, whereas the micronized kaolin reagent was unable to detect this deficiency. All three reagents were insensitive to all but severe deficiencies in high-molecular-weight kininogen. The authors conclude that the reagent systems tested, containing micronized silica or ellagic acid as activators, are similar in sensitivity when used in a routine activated partial thromboplastin time to screen for factor deficiencies, whereas the reagent system containing micronized kaolin as an activator is less sensitive.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3940420     DOI: 10.1093/ajcp/85.1.43

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  5 in total

1.  A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release.

Authors:  K-A Steen Burrell; J Layzer; B A Sullenger
Journal:  J Thromb Haemost       Date:  2017-08-02       Impact factor: 5.824

2.  Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding.

Authors:  Alexey S Revenko; Dacao Gao; Jeff R Crosby; Gourab Bhattacharjee; Chenguang Zhao; Chris May; David Gailani; Brett P Monia; A Robert MacLeod
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

3.  Massive transfusion and coagulopathy: pathophysiology and implications for clinical management.

Authors:  Jean-François Hardy; Philippe de Moerloose; Charles Marc Samama
Journal:  Can J Anaesth       Date:  2006-06       Impact factor: 5.063

4.  Influence of chronic kidney disease on anticoagulation levels and bleeding after primary percutaneous coronary intervention in patients treated with unfractionated heparin.

Authors:  Wouter J Kikkert; Peter M van Brussel; Peter Damman; Bimmer E Claessen; Jan P van Straalen; Marije M Vis; Jan Baan; Karel T Koch; Ron J Peters; Robbert J de Winter; Jan J Piek; Jan G P Tijssen; Jose P S Henriques
Journal:  J Thromb Thrombolysis       Date:  2016-04       Impact factor: 2.300

5.  Antibody inhibition of contact factor XII reduces platelet deposition in a model of extracorporeal membrane oxygenator perfusion in nonhuman primates.

Authors:  Michael Wallisch; Christina U Lorentz; Hari H S Lakshmanan; Jennifer Johnson; Marschelle R Carris; Cristina Puy; David Gailani; Monica T Hinds; Owen J T McCarty; András Gruber; Erik I Tucker
Journal:  Res Pract Thromb Haemost       Date:  2020-02-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.